Exciting news for people living with idiopathic pulmonary fibrosis (IPF). Two large clinical trials TETON-1 and TETON-2 showed that an inhaled medication called treprostinil (Tyvaso) slows the loss of lung function in patient with … [Read more...]
Staying Healthy in Winter
In America, we have entered a new era—One in which you can’t rely on the federal government for good healthcare guidance. For the first time in my three decades in medicine, the federal government is no longer to be trusted with respect to medical advice. This creates a confusing mess for patients looking to make good decisions. In an unprecedented situation, medical … [Read more...]
Nerandomilast in Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis: A Promising New Therapeutic Approach
Introduction Idiopathic Pulmonary Fibrosis (IPF) is a progressive and often fatal interstitial lung disease marked by chronic fibrosis and inflammation of lung tissue. IPF remains a significant therapeutic challenge despite the availability of antifibrotic agents like pirfenidone and nintedanib. Recent attention has turned toward inflammation-modulating and immunoregulatory … [Read more...]
Interstitial Lung Disease and Progressive Pulmonary Fibrosis
Disorders characterized by inflammation or scarring in the lungs may be the most complicated area within lung medicine. Not only are the names confusing but they have repeatedly changed over the past 50 years. Furthermore, many of the early studies describing the natural history of one disease or another have turned out to be inaccurate. To make … [Read more...]
Pamrevlumab Ineffective in Treating IPF
In June of 2023 Fibrogen announced the results of the ZEPHYRUS-1 clinical trial of Pamrevlumab in IPF. Pamrevlumab entered phase 3 with much anticipation. Phase 2 work suggested that the molecule had a high chance of success. Unfortunately, in the phase 3 study which included 356 subjects, Pamrevlumab was not effective at preserving lung function. As a result, Fibrogen … [Read more...]